SKLB06329

SKLB06329 is a potent and selective inhibitor of type I PRMTs. It demonstrates strong selectivity for PRMT6 (IC50= 3.86 nM) without significantly inhibiting type II/III PRMTs (such as PRMT5/7) or various protein lysine methyltransferases [PKMTs]. SKLB06329 effectively suppresses the proliferation of triple-negative breast cancer [TNBC] cells, induces apoptosis, and inhibits the expression of asymmetric dimethylarginine [ADMA] within cells. This compound is applicable for research related to triple-negative breast cancer.